Drug Profile
Botulinum toxin A - Ipsen
Alternative Names: AboBoNT-A; AbobotulinumtoxinA; ALLUZIENCE; Azzalure; BoNT-A; BTX-A-HAC; BTX-A-HAC NG; Clostridium botulinum toxin type A haemagglutinin complex; Dysport; DYSPORT AESTHETIC; Dysport NG; Dysport RU; Dysport Solution; Dysport® Next Generation; ReloxinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Health Protection Agency Porton Down; Ipsen Limited
- Developer Biosintetica; Galderma; Ipsen Limited; Medicis Pharmaceutical Corporation; Valeant Pharmaceuticals International
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Blepharospasm; Equinus foot deformity; Facial wrinkles; Fissure in ano; Glabellar lines; Hyperhidrosis; Muscle spasticity; Neurogenic bladder; Spasm; Torticollis
- Phase III Migraine; Musculoskeletal disorders; Urinary incontinence
- Phase II/III Pain
- Phase II Gilles de la Tourette's syndrome; Gingival disorders; Vulvodynia
- Discontinued Hallux valgus
Most Recent Events
- 12 Oct 2023 Ipsen initiates enrolment in a phase III C-BEOND trial for Migraine in USA (NCT06047444)
- 29 Sep 2023 Phase-III clinical trials in Migraine (Prevention) in USA (IM) (NCT06047457)
- 21 Sep 2023 Ipsen plans a phase III trial for the prevention of Migraine in undisclosed location (NCT06047444)